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Abstract: Manned space flight induces a reduction in immune competence among crew and 
is likely to cause deleterious changes to the composition of the gastrointestinal, nasal, and 
respiratory bacterial flora, leading to an increased risk of infection. The space flight environ-
ment may also affect the susceptibility of microorganisms within the spacecraft to antibiotics, 
key components of flown medical kits, and may modify the virulence characteristics of bacteria 
and other microorganisms that contaminate the fabric of the International Space Station and 
other flight platforms. This review will consider the impact of true and simulated microgravity 
and other characteristics of the space flight environment on bacterial cell behavior in relation 
to the potential for serious infections that may appear during missions to astronomical objects 
beyond low Earth orbit.
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Introduction
A new chapter in human space flight is opening: at one end of the spectrum, a fledging 
space tourism industry has emerged, and for the first time in many years, the possi-
bility of exploration beyond low Earth orbit (LEO) is firmly on the agenda. As more 
nation states become involved, the momentum of manned space flight will inevitably 
increase and will eventually extend humanity’s reach far into the solar system. The 
current focus of human activity in space is the International Space Station (ISS), the 
largest, most complex international scientific and engineering project conceived to 
date. The ISS has been continuously occupied since November 2000 and is likely to 
function as a research base for another 5–10 years. The ISS provides a platform for 
on-orbit long-duration (up to 215 days) studies to examine the impact of the space 
flight environment on human health and physiology and an opportunity to develop 
countermeasures that will sustain crew health during voyages into deep space. Although 
the enormous cost of building and maintaining the ISS has imposed severe financial 
and political constraints on planning missions beyond LEO, intent has been signaled 
for a return to the Moon and manned expeditions to Mars, near-Earth asteroids such 
as Ida and protoplanets in the asteroid belt such as Ceres, which are likely within 
the next 30–50 years.1 For example, in spite of formidable technical, physical, and 
psychological barriers, NASA is developing capabilities to send human beings to 
an asteroid by 2025 and to Mars in the 2030s. In addition to exploratory missions, 
commercial–industrial activities may open up the potential for mining of minerals and 
fuel on the Moon or near-Earth asteroids.2,3 Expeditions beyond Earth orbit present 
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huge challenges in order to maintain the health of those on 
board.4–8 Lunar missions will last weeks or months and Mar-
tian expeditions will be of 2–3 years duration with little or 
no opportunity for evacuation of sick crew members should 
a medical emergency arise. In contrast, ISS crew typically 
spend 6 months on the platform and comprehensive plans 
are in place for immediate emergency evacuation.9 Crew 
on short-duration missions frequently experience minor 
trauma, burns, dermatological and musculoskeletal condi-
tions, respiratory problems, headache, insomnia, and, most 
common of all, space motion sickness.5,10 In consequence, 
the crew members are trained to adopt first-aid treatments, 
resuscitation procedures, and other interventions including 
wound stitching and injection,11 which are supported by 
remote monitoring and distance support by Earth-based 
clinical specialists12 and an onboard medical kit containing 
a wide range of medications, including a substantial number 
of antibiotics formulated for topical and systemic use.13,14 
There is no documented evidence that microbial infection has 
led to the abortion of a space flight but localized infections 
have caused significant problems during orbital missions; 
these include conjunctivitis and acute respiratory and dental 
infections.4 Among the most prominent was a severe dental 
infection suffered by cosmonaut Yury Romanenko during 
an extended flight aboard Salyut 6. He suffered debilitating 
toothache for .2 weeks, which was only remedied on his 
return to the Earth: the Soviets had no contingency plan in 
place to deal with dental emergencies and Romanenko’s 
ordeal was the subject of a televised interview in his own 
country and accounts in the Western dental literature.15 
Although data for US missions are sketchy, 26 instances of 
infection were reported for American astronauts during the 
Space Shuttle program STS-1 to STS-89 over the period 
April 1989 to January 1998.4 Routine preflight quarantine 
has significantly reduced the incidence of infections during 
missions but the risk remains and is likely to be considerable 
on future missions into deep space: the spacecraft interior 
will be contaminated with a wide range of microorganisms; 
injury and trauma, such as lacerations and open fractures, 
are likely to occur, and there is strong evidence that extended 
spaceflight compromises the immune system.16,17 In addi-
tion, bacteria are adept at adapting to new environments 
and studies reporting some potentially pathogenic bacteria 
display increased virulence in microgravity are a further 
cause for concern. This review will examine the impact of 
the space flight environment on the capacity of bacteria to 
cause infections in space farers and will appraise the likely 
risks for astronauts undertaking extended space flight.
Host factors affecting susceptibility 
of crew to infection
Astronauts require a wide range of skills and capabilities in 
order to perform effectively in the unique closed environ-
ment of orbiting spacecraft and to be fit and healthy from 
both medical and psychological perspectives. The decrease 
in load bearing for bones of the lower body afforded by 
reduced gravity results in resorption of bone mineral, 
muscles weaken and atrophy, fluids are redistributed to the 
upper body, lengthening of the spine may induce back pain, 
and the neural circuits that govern balance are disturbed.18 
These effects are only partly offset by countermeasures that 
include exercise and pharmaceutical interventions. These 
physiological changes will have a major impact on the overall 
health status and are likely to be compounded by enormous 
psychosocial pressure within small isolated groups, particu-
larly during extended space flight.4 The immune system is 
moderately compromised by space flight, although there is 
little to suggest flight-induced immune deficits acquired 
during short- to medium-duration missions result in serious 
illness.19 For example, about half of the astronauts who flew 
Apollo missions reported minor bacterial or viral infections 
within a week of their return but the effects were strictly short 
term.20 More recently, reactivation of latent herpes viruses, an 
indicator of downregulation of cellular immunity, has been 
noted in crew during flight and within 1 week of return.16,21 
Mehta et al22 recorded subclinical activation of Epstein–Barr 
virus, varicella-zoster virus, and cytomegalovirus in 14 of 
17 astronauts undertaking short-duration flights on board 
the Space Shuttle, in marked contrast to a terrestrial control 
group. Thus, the appearance of serious immune-related 
disorders during extended missions outside LEO cannot be 
discounted.
Human and animal studies show that space flight or 
analog environments impact on specific elements of immune 
function. Modifications include proliferation of human 
leukocytes in response to mitogenic stimulation, reductions 
in the synthesis of interferons α and β, inhibition of natural 
killer cell activity, depression of delayed-type hypersensitiv-
ity reactions, and alteration of leukocyte subpopulations in 
the marrow and spleen.21 As the cellular components of the 
immune system play a central role in the control of bacterial 
and viral pathogens, limiting their ability to colonize, invade, 
and spread within the body, it is significant that space flight 
induces reversible hypoplasia in the organs of the lymphoid 
system. After 3 weeks in LEO, the weight of the spleen and 
thymus of rats was found to be significantly reduced, with 
accompanying decreases in the number of lymphocytes 
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and erythroid cells of the spleen and lymphocytes of the 
thymus and lymph nodes.23 Lymphoid organ hypoplasia has 
been confirmed in mice on two US Shuttle flights of similar 
duration to the Soviet mission.24,25 In apparent contradiction, 
there have been a number of consistent reports, summarized 
by Guéguinou et al,26 showing increases in circulating neu-
trophils of human beings and animals subjected to LEO of 
varying duration, immediately after landing, although these 
authors point out that the enormous stress of landing may be 
responsible for these increases due to mobilization of bone 
marrow polymorphonuclear leukocytes into the circulation. 
Space flight suppresses the function of cellular components 
of both the innate and adaptive immune response. Thus, 
neutrophils, macrophages, and NK cells respond less readily 
to various stimuli compared to terrestrial controls17,27,28 and 
T-lymphocytes from space crew display decreased responses 
to mitogens when harvested after landing.29 Interestingly, 
women demonstrate a stronger immune response to various 
stimuli than men and this could be taken into account for crew 
selection. Although inclusion of female crew members has 
increased in the recent past, there are currently insufficient 
number of female subjects to determine unequivocally if 
sex is a factor that impacts significantly on crew wellbeing 
both during space flight and during the postflight recovery 
period.30
These immune deficits are reminiscent of data from 
Arctic and Antarctic expedition team members, submari-
ners, and others who may be isolated in time and confined 
within closed environments31 and may be an unavoidable 
consequence of long periods of isolation or confinement. 
There are a range of opportunistic pathogens, including 
bacteria, fungi, and viruses, which depend on reduced 
immune function to cause serious infectious diseases, and 
some of them will inevitably accompany the crew into orbit 
or deep space. The major source of potential infection aboard 
spacecraft is provided by the astronauts’ own bacterial flora. 
The human body is home to a large and diverse community 
of microorganisms, collectively termed the microbiome, 
that play an active role in the development and function of 
a range of physiological processes of the host,32 including 
the orchestration of the mucosal immune response.33 These 
microbial populations consist largely of bacteria and reside 
on the skin and in the oral cavity, nasal passages, urogenital 
tract, and, predominantly, the gastrointestinal (GI) tract. 
The healthy human adult GI tract contains a complex 
community of bacteria comprising ∼1,000 species,34 and 
perturbation of this population may result in manifestation 
of disease.34–36 Many of these bacteria cannot be cultured 
but recent developments in metagenomic technology have 
enabled detailed analysis of the GI microbial flora by 
sequence determination of small-subunit ribosomal RNA 
genes without the need for culture.37
Through use of traditional culture techniques, evidence 
has accumulated that the intestinal bacterial community 
of crew members undergoes significant change during 
spaceflight. Early Soviet studies indicated that as early 
as 2 weeks into confinement on Salyut and Mir orbiting 
platforms, significant reductions in the number of bacte-
rial species cultured from the GI tract were evident, as was 
interchange of intestinal bacteria between crew members.38,39 
In a similar fashion, the number of distinct bacterial spe-
cies within the GI tract of astronauts on board Apollo and 
Skylab was markedly reduced and robust Gram-negative 
aerobic species such as potentially pathogenic Klebsiella and 
Pseudomonas emerged.20 Significant reductions in beneficial 
intestinal lactobacilli from cosmonauts prior to launch have 
been recorded,40 an indication that preflight stress may drive 
changes in the composition of the gut microbiota, a view 
supported by a study under simulated Skylab conditions.41 
Evidence has emerged of a subtle interplay between the gut 
microbiota and the immune and endocrine systems in the 
maintenance of homeostasis;32 stress and other potential 
disrupters of the microbiome–brain–gut axis will impact on 
the composition of the microbiome and are likely to account 
for preflight and in-flight changes to the bacterial content of 
the gut described here, but more work needs to be undertaken 
in this important area. As of June 2015, no reports using 
metagenomic analyses of GI microbiota of flight crew have 
appeared but an on-orbit study of astronaut microbiota using 
state-of-the-art genetic technology, NASA’s Microbiome 
experiment,42 will appear soon.
Impact of the space flight 
environment on bacterial physiology
Although bacteria have evolved to survive in sometimes 
hostile terrestrial niches and will not have previously encoun-
tered the environment within the confines of spacecraft 
traveling beyond Earth’s gravitational field, they are able to 
sense, respond, and adapt to changes in their surroundings. 
In addition to low or zero gravity, they will be exposed to 
vibration, acceleration, and radiation in the form of galactic 
cosmic rays and solar energetic particle events at levels not 
encountered elsewhere.43 There is general agreement that 
microgravity represents the major influence on bacterial 
growth kinetics and bacterial cell behavior during short 
orbital flights, although radiation may increase microbial 
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mutation rates during flight: after 40 days aboard Mir, 
mutation rates for a cloned bacterial gene carried by a yeast 
were two to three times higher than the ground control.44 
Investigations conducted during short orbital flights suggest 
that a range of bacteria display increased metabolic activity 
in space, manifest as a shorter lag phase, increased biomass, 
and increased production of secondary metabolites,45–47 
although some comparable studies reported no differences 
between flight cultures and terrestrial controls.48,49 Some of 
these observations have been confirmed aboard multiple 
Space Shuttle flights: the consistency of the data obtained 
makes it unlikely that disparities of outcome are due to a lack 
of reproducibility resulting from the technical difficulties 
inherent in conducting scientific experiments in low gravity, 
implying that differences in growth media, culture conditions, 
strain-to-strain variations, and the nature of the bioreactors 
inside the spacecraft habitat account for differing responses 
to the space flight environment.43,50 Differential impact of 
bacterial cell behavior in microgravity could be exploited 
for the production of pharmaceutical compounds, secondary 
metabolites, and vaccines.
It is clear that earlier predictions51 based on theoretical 
calculations that bacteria are too small to be affected by 
gravitational forces are incorrect. Klaus et al,46 and Benoit 
and Klaus52 have suggested that bacteria are affected only 
indirectly by microgravity due to the quiescent fluid envi-
ronment surrounding the cells in liquid suspension culture. 
The settling of cells through liquid media and the potential 
for buoyant convection of less dense fluid in the vicinity of 
suspended bacteria are massively reduced in microgravity, 
and diffusion becomes the predominant means of nutrient 
transport toward and of metabolic waste away from the 
cell.52 The view that fluid dynamics and extracellular trans-
port phenomena rather than cellular dynamics contribute to 
microgravity-induced differences in liquid-culture growth 
kinetics is supported by observations that bacteria such 
as Escherichia coli and Bacillus subtilis cultured on solid 
medium during flight grow at the same rate and to the same 
extent as terrestrial controls.49,53 A strong correlation has been 
noted between the impact of space flight on growth kinetics 
and bacterial motility, which goes a long way toward explain-
ing differences between flown experiments in this area.52 
Thus, differences between microgravity-induced growth 
effects and ground controls seem to be, in the main, evident 
only when the bacteria under investigation are flagellate: 
clearly, motile cells have the capacity to seek out microen-
vironments in liquid cultures that have not been depleted of 
nutrients and flagellar action may in itself mix the quiescent 
layer around the cell. Although no definitive experiments have 
been undertaken to underpin this contention, studies with 
microgravity analogs such as clinostats and the high aspect 
ratio vessel (HARV), a rotating wall bioreactor described 
below, support the idea that mixing of microgravity-grown 
cultures to eliminate differences in fluid dynamics abrogates 
these growth kinetic effects.
Alterations in bacterial growth kinetics in space appear 
to stimulate the production of secondary metabolites. Thus, 
production of the antibiotic monorden by the parasitic fun-
gus Humicola fuscoatra was greater when grown aboard 
Space Shuttle mission STS-77 than in ground samples,54 
even though agar media were employed. Similarly, the time 
course of elaboration of the antibiotic actinomycin D by 
Streptomyces plicatus in both defined and complex liquid 
media was altered in comparison to terrestrial cultures during 
flight on Shuttle STS-80, with more of the drug produced dur-
ing the first 12 days in orbit.55,56 Interestingly, flight samples 
maintained their sporulation capacity when plated on agar 
medium postflight, while the residual ground controls did 
not sporulate.
Some microorganisms adapt and thrive in the unique envi-
ronment within spacecraft. A cloudy humidity condensate 
collected in January 1998 from behind a service panel on 
the orbiting platform Mir contained a wide range of bacteria, 
including Gram-negative species only infrequently associated 
with the contamination of short-duration missions.57 One 
sample yielded evidence of a member of the genus Legio-
nella, bacteria that can cause lethal infections. Microbial 
consortia that accumulated over the 12 years since the launch 
of Mir included fungi of medical importance, protozoa, dust 
mites, and spirochetes. Some bacteria were recovered from 
surfaces in biofilms, suggesting a microbial strategy for 
increased onboard survival in comparison to less developed 
bacterial communities. Pseudomonas aeruginosa PAO-1 
formed biofilms more readily than in Earth-based parallel 
experiments when grown on surfaces or solid medium in 
the Biorack facility aboard Shuttle missions STS-8158 and 
STS-95.59 During later missions STS-132 and STS-135, 
P. aeruginosa biofilms exhibited a “column and canopy” 
structure that has not been observed on Earth;60 thus, space-
flight affects not only the physiology of planktonic bacterial 
cultures but also their community-level behavior. A high 
proportion of Gram-positive isolates from the ISS were able 
to grow as biofilms under standard laboratory conditions,61 
suggesting that the capacity to form complex communities 
on surfaces and interfaces provides competitive advantage 
aboard spacecraft.
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Microbial contamination of 
spacecraft
Spacecraft are manufactured in ultraclean facilities com-
parable to those used for the manufacture of medicines, 
and extensive precautions are taken to ensure that levels 
of microbial contamination are minimized. Until recently, 
culture-dependent techniques appeared to indicate that 
the low microbial burden associated with assemblies 
such as Mars Odyssey comprised predominantly robust, 
sporulating species of the genus Bacillus but more recent 
culture-independent studies have revealed a broader range 
of Gram-positive and Gram-negative bacteria, as well as 
actinomycetes and fungi.62,63 Indeed, a comprehensive 
investigation of microbial contamination of the Mars rover 
Curiosity revealed that more than 350 distinct strains of 
bacteria survived rigorous decontamination in the clean room 
at NASA’s Jet Propulsion Laboratory in Pasadena.64 Many 
such contaminants are resistant to extreme temperatures and 
ultraviolet-C-mediated damage,62,65 and steps are being taken 
to assemble a genetic inventory of spacecraft contaminants 
to ensure that attempts to study the potential for indigenous 
Martian life are not compromised.66 Although these envi-
ronmental extremophiles may represent a threat to the fabric 
of the spacecraft infrastructure through biofouling, they are 
unlikely to pose a health risk to crew.
A greater microbial risk to crew wellbeing will come 
from their commensular flora, which will inevitably colonize 
the spacecraft, and from microbes originating from onboard 
supplies of air, food, and water. For example, it was reported 
that potable water generated by the fuel cells aboard Space 
Shuttle flights was commonly contaminated with very low 
levels of Burkholderia cepacia and other problematical 
bacteria.67 Similarly, potable water brought from ground 
sources and stored aboard Mir67 or the ISS68 tended to display 
higher bacterial counts than reclaimed humidity condensate. 
Future extended duration missions are expected to employ 
microorganisms for solid waste remediation and as a food 
source.67 On such missions, onboard cultivation of plants as 
food or as a component of bioregenerative life-support sys-
tems together with transportation of associated agricultural 
materials will further contribute to microbial complexity 
within such closed environments. The extent and complex-
ity of microbial contamination will increase with time away. 
Although the potential health impact from the development 
of diverse microbial populations is unclear, these findings 
emphasize that microbial monitoring and vessel disinfec-
tion are significant factors to be taken into consideration in 
habitat design, engineering, and operation of all spacecraft. 
Threats may come not only from bacteria but also from fungi; 
dust in HEPA filters from the US laboratory aboard the ISS 
contained a wide range of potentially pathogenic molds such 
as Aspergillus flavus and Aspergillus niger and moderate 
toxin producers such as Penicillium chrysogenum and Penicil-
lium brevicompactum.69 Fifteen years of continuous human 
occupation of the ISS has made the station an excellent test 
bed for the prediction of microbiological problems that will 
be encountered during future deep space exploration mis-
sions. The approach to microbiological risk on the ISS is one 
of the prevention rather than reliance on in-flight solutions, 
and highly efficient air filtration systems, microbiological 
monitoring, and features to minimize the accumulation of 
moisture have been incorporated into its design.67 Neverthe-
less, the structural and electronic complexities of the various 
modules that comprise the ISS are so high that routine clean-
ing of surfaces represents a major “housekeeping” challenge 
(Figure 1). The initial colonization of surfaces on board the 
Russian segment of the ISS has recently been investigated:70 
polymeric materials such as cable-labeling polyimide and the 
flame-resistant aramid Nomex® were particularly prone to 
pioneer colonization by dominant Gram-positive members 
of the genera Staphylococcus, Micrococcus, Bacillus, and 
Streptococcus, indicating that the skin of crew members 
represents the primary source of early contamination. Gram-
negative bacteria and fungi were also evident.
The international partners on the ISS (NASA, European 
Space Agency [ESA], Japan Aerospace Exploration Agency 
[JAXA], and Russian Federal Space Agency [RFSA]) rou-
tinely monitor the station to provide essential microbiological 
information for crew safety. Data for the first 5 years occupa-
tion of the Russian segment were revealed in publications from 
Natalia Novikova of the Russian Academy of Sciences.71,72 
Some 500 air, water, and surface samples were examined; 
viable microorganisms in potable water were invariably ,100 
per mL, and the number of airborne bacteria and fungi was 
710 and 44 per m3, respectively. Bacterial contamination of 
surfaces fluctuated between 25 per 100 cm3 and 43,000 per 
100 cm3 according to sampling location. Predominant bac-
teria were members of the genus Staphylococcus, isolated 
from 84% of air and surface samples. Staphylococcus aureus 
and other opportunistic pathogenic species were frequently 
recovered. This study established that the environment within 
the ISS is dominated by bacterial species associated with 
the skin and mucous membranes of the crew members, in a 
fashion not dissimilar to that of a medical care unit. In total, 
.70 species of microorganisms were found, about half being 
bacteria and half fungi, demonstrating the appearance of a 
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remarkable biodiversity that had developed over a relatively 
short period of time. These observations have been confirmed 
and extended to encompass sampling of NASA’s Destiny 
Laboratory68,73 (Figure 1) and JAXA’s Kibo facility aboard 
the ISS.73 Again, Staphylococcus, Bacillus, and Micrococcus 
were the most frequently recovered bacterial genera from air 
and surface samples between August 1998 and August 2011. 
Antibiotic resistance appears to be a common trait among 
these isolates; 22 of 29 Staphylococcus and Enterococcus 
isolates were resistant to at least one antibiotic deployed 
aboard the ISS, and most were capable of forming biofilms,61 
a likely reflection of their capacity to colonize and persist 
within the orbiting station.
The space flight environment and 
antibiotic susceptibility
If infections were to occur on extended missions, their treat-
ment could be compromised by reversible or irreversible 
increases in antibiotic resistance. Tixador et al,74 and Moatti 
et al,75 briefly described some otherwise unpublished obser-
vations made during the Apollo–Soyuz Test Project76 that 
bacteria cultured from astronauts during flight were more 
resistant than isolates obtained from the same individu-
als either pre- or postflight. These observations prompted 
the design and execution of experiments to determine the 
antibiotic susceptibility of S. aureus and E. coli isolates 
from the nasal and GI microbiota of the French astronaut 
Jean-Loup Chrétien aboard Salyut 7 in July 1982 as part of 
the Cytos 2 program. Chrétien carried out these experiments 
during orbital flight, and the data were compared to ground 
controls.74,77
Onboard minimal inhibitory concentrations (MICs) 
for colistin and kanamycin against the E. coli isolate were 
reported as .16 µg/mL compared to control values of 
4 µg/mL for both antibiotics. For the S. aureus isolate, 
the ground control values of 0.16 µg/mL, 4 µg/mL, and 
0.5 µg/mL against oxacillin, chloramphenicol, and eryth-
romycin, respectively, increased approximately twofold 
aboard the orbital station. The severe restrictions imposed 
by space flight and the fact that the laboratory operator was 
an astronaut rather than a microbiologist determined that the 
bioassay readouts were based on a pH-induced color change 
rather than a turbidity endpoint. It is unlikely that the small 
differences in the staphylococcal MICs are significant given 
the technical limitations of the bioassay.78 Chrétien also 
embedded the S. aureus isolate in resin during the Soyuz 
7 flight, and sections were later compared by transmission 
electron microscopy to ground controls (Figure 2). While 
Figure 1 Internal complexity of the ISS.
Notes: (A) NASA astronaut Dan Burbank, Expedition 30 commander, conducts a 
session with the Preliminary Advanced Colloids Experiment at the Light Microscopy 
Module. (B) Expedition 22 flight engineer Tim Creamer works with flex hoses in the 
ISS’s US Destiny laboratory. (C) Using a vacuum cleaner. Courtesy of NASA.
Abbreviation: ISS, International Space Station.
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the terrestrially grown bacteria had an appearance typical of 
S. aureus, with clearly differentiated cell walls and septum 
formation in the orthogonal plane of cell division, the flown 
bacteria had an unusual ultrastructure, which has been 
interpreted as showing a greatly increased thickness of 
the cell wall peptidoglycan layer,77,79 typical of alterations 
in vancomycin antibiotic susceptibility.80,81 However, the 
appearance of the in-flight-grown cells has little semblance to 
conventionally grown staphylococci and the layers external to 
the cytoplasmic membrane appear less dense than those asso-
ciated with staphylococci with thickened cell walls caused 
by phenotype modification.82 In addition, the cell surface 
appears to be blebbing, a phenomenon that occurs during 
normal growth of Gram-negative bacteria and is enhanced 
in certain mutants that are impaired in cell division,83 sug-
gesting that the bacteria embedded in resin aboard Soyuz 7 
are contaminants and not S. aureus cells undergoing major, 
reversible physiological modification due to the impact on 
morphology of the space flight environment. The changes in 
antibiotic susceptibility were reversible, as bacteria recovered 
from the Soyuz 7 flight did not display increased antibiotic 
susceptibility over ground-based controls when subcultured 
in a terrestrial laboratory.77 In this context, it would be 
instructive to repeat these experiments aboard the ISS using 
more recently developed in-flight methodologies in order to 
resolve this important issue.
The difficulties encountered in such in-flight experiments 
are illustrated by additional work undertaken in November 
1985 aboard Space Shuttle Challenger flight STS-61-A dur-
ing the ESA Biorack program Antibio79 and Discovery flight 
STS-42 as part of the International Microgravity Labora-
tory mission in January 1992,84 both to determine, in fairly 
restricted fashion, the impact of space flight on antibiotic 
susceptibility. Both flights included onboard centrifugal 
controls to allow for additional effects such as vibration and 
acceleration relative to ground controls. The MIC of E. coli 
Seattle 1946 (ATCC 25922) against colistin was determined 
aboard STS-61-A on a static rack under microgravity and 
on an in-flight centrifuge at 1× g. Although published details 
are sketchy,79 a colorimetric procedure similar to that of the 
earlier Franco-Soviet flight was used and the data compared 
to static rack 1× g and 1.4× g centrifugal Earth controls. 
Both in-flight determinations (microgravity and 1× g) gave 
MICs of 2 µg/mL; these values were double those obtained 
with both Earth controls,79 suggesting that factors other than 
those relating to the gravitational field were responsible for 
these small, possibly insignificant, differences. Large, 100-
fold differences in colony forming units counts between 
in-flight (higher) and ground controls (lower) at correspond-
ing inhibitory concentrations were claimed79 but no details 
of any standardization of respective inocula were provided, 
and it is well established, as detailed in the section Impact of 
the space flight environment on bacterial physiology of this 
review, that bacteria have the capacity to grow faster under 
Figure 2 Ultrathin sections of Staphylococcus aureus grown as (A) terrestrial control 
and (B) in-flight aboard Salyut 7 by Chrétien in 1982 for the Cytos 2 program.
Note: Images from Tixador et al77 with permission from Elsevier.
Infection and Drug Resistance 2015:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
256
Taylor
microgravity, particularly under static growth conditions. 
Although it is tempting to conclude that these data are 
indicative of a microgravity-induced increase in antibiotic 
resistance,79,85 it should be treated with caution. Similarly, 
differences in the growth rate of the E. coli Seattle strain in 
the presence and absence of subinhibitory concentrations of 
dihydrostreptomycin aboard STS-42 produced inconclusive 
results when in-flight and ground controls were compared. 
MICs appeared identical (8 µg/mL) between ground and 
flight determinations, although there were differences in 
growth curve profiles at 6 µg/mL that suggested subtle 
changes in the interaction between the antibiotic and the 
ribosomal target. In agreement with the study conducted 
within the Antibio program, no differences were observed 
between cultures developed in-flight in the 1× g centrifuge 
and those placed in the static rack under reduced gravity. 
Kacena and Todd,86 in demonstrating that E. coli grown 
on solid agar medium aboard STS-69 and STS-73 were as 
susceptible to gentamicin as ground controls, highlighted 
the caution to be taken in the interpretation of in-flight 
antibiotic sensitivity testing, particularly when suspension 
culture is used. The anomalies generated by this confusing 
body of work can only be completely resolved by further 
in-flight experimentation undertaken in systematic fashion. 
Unfortunately, opportunities for experimentation aboard 
orbiting stations are currently very limited.
Bacterial growth under modeled 
microgravity: virulence  
and antibiotic susceptibility
The space flight environment is inherently complex, with 
multiple variables that include zero and microgravity, 
acceleration, vibration, radiation, electromagnetism, and 
additional environmental stresses associated with the closed 
environment of the space vehicle, and cannot therefore be 
simulated in its entirety.87 These factors may impact indi-
vidually on bacterial physiology and result in changes to 
gene expression and behavior, but their combined effect can 
only be examined simultaneously during actual space flight. 
Examination of space flight parameters are limited by the 
constraints of in-flight experimentation, such as requirements 
for the development of specialized equipment and restric-
tions imposed on power, weight, and volume. The intense 
competition for the crew’s time dictates that experiments 
are simple to perform with little or no crew involvement. 
These severe limitations can be overcome to a considerable 
extent through the use of ground-based devices that simulate 
individual aspects of space.
Clinostats and other rotating wall bioreactors such as 
the HARV have stimulated a large body of research into the 
impact of modeled microgravity on the physiology of a wide 
range of unicellular85 and multicellular88 cells, including 
microorganisms. The HARV, developed at the NASA John-
son Space Center,89 consists of a hollow cassette completely 
filled with growth medium that slowly rotates on an axis 
parallel to the ground; under these conditions, the bacteria 
are continually suspended in the medium, falling through a 
sustained low-shear (,1 dyn/cm2) environment that simulates 
true microgravity. Thus, this low-shear modeled microgravity 
(LSMMG) device uses constant reorientation in suspension 
culture to effectively nullify cumulative sedimentation of 
particles but cannot fully reproduce the concurrent lack of 
structural deformation, displacement of intercellular com-
ponents, and reduced mass transfer in the extracellular fluid 
that occur in the true weightless environment.90 When the 
HARV is employed in the LSMMG orientation with the axis 
of rotation at 25 rpm and perpendicular to the direction of the 
gravity force vector, the bioreactor simulates a gravitational 
field of ∼0.01× g;91 rotating the vessel in the normal gravity 
orientation at 90° to the perpendicular, the axis of rotation 
is parallel to the gravity vector, providing a 1× g control that 
can be run in parallel with LSMMG cultures. The engineer-
ing principles behind these devices, that create a low-shear 
mixed fluid environment optimized for suspension culture, 
have been described in detail in two excellent reviews.89,90
In a comprehensive series of publications, Nickerson 
et al have explored the impact of growth in ground-based 
microgravity analogs on the virulence of Salmonella enterica 
serovar Typhimurium, a human and animal pathogen that 
frequently causes GI infections. Time to death of mice 
administered LSMMG-grown cells by the oral route was 
shorter in comparison to the same dose of 1× g control 
bacteria; LSMMG-grown bacteria more readily colonized 
the liver and spleen, possessed a decreased LD
50
, and were 
more acid resistant. It is not clear how the bacteria grown 
under LSMMG conditions maintained their microgravity 
phenotype throughout the 20-day period of the mouse viru-
lence assay;92 they would be expected to revert to normal 
phenotype after reencountering 1× g conditions, but they 
may have retained the induced phenotype for sufficient time 
to enable them to pass through the acidic environment of the 
stomach. LSMMG differentially regulated the expression of 
163 genes representing functionally diverse activities,93 and 
it was proposed that modeled microgravity elicits a novel 
environmental signal, possibly mediated by the fur product, 
which regulates virulence, stress resistance, and protein 
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expression in S. enterica, enabling the cell to “fine tune” 
the expression of virulence mechanisms in novel fashion. 
This ground-based data enabled the evaluation of transcrip-
tomic and proteomic responses of S. enterica aboard Space 
Shuttle flight STS-115;94 167 transcripts and 73 proteins 
were found to display altered expression in comparison to 
ground control cultures, and the conserved RNA-binding 
protein Hfq was identified as a likely global regulator of the 
flight-induced response.
The LSMMG response appears to be conserved by other 
Gram-negative bacteria.95 However, as discussed above, 
Gram-positive bacteria such as S. aureus are likely to pose a 
much greater risk of opportunistic infection to the crew than 
S. enterica, which is unlikely to be encountered during space 
flight. Taylor and Rosado96–98 examined the effect of simu-
lated microgravity in the HARV on parameters of antibiotic 
susceptibility and virulence in methicillin-susceptible clinical 
isolates of S. aureus. Only very small differences in growth 
kinetics over the 24-hour culture period were seen with the 
three isolates, and there were no significant differences in 
susceptibility to erythromycin, flucloxacillin, or vancomycin 
when cells were grown under LSMMG compared to normal 
gravity; the antibiotics were selected on the basis of their dif-
fering mechanisms of action. In marked contrast to the images 
obtained from S. aureus cultured aboard Salyut 7 (Figure 2), 
there were no discernible differences in staphylococcal cell 
morphology as revealed by scanning and transmission elec-
tron microscopy. The three S. aureus isolates produced the 
carotenoid pigment staphyloxanthin, a triterpenoid esterified 
with a C15 fatty acid and linked to staphylococcal virulence;99 
all three isolates produced less staphyloxanthin when grown 
under simulated microgravity compared to normal gravity 
cells. Large decreases in total protein secretion and in the 
elaboration of extracellular α, β, γ, and δ hemolysins were 
also evident. There was, however, only a modest reprogram-
ing of gene expression in all strains with up to 25 genes 
differentially expressed under LSMMG. The only common 
feature among the three isolates examined was a substantial 
downregulation of vraX, a gene encoding a small (55 amino 
acids) compact polypeptide that is massively upregulated in 
the stress response to cell wall-active antibiotics100 and other 
surface-interactive molecules.101 VraX harbors a putative 
phosphorylation site,102 and could therefore be involved in 
regulatory processes within the cell, although a ∆vraX mutant 
did not appear to differ from the wild type with respect 
to protein secretion and had no influence of the expres-
sion of other staphylococcal genes under the experimental 
conditions used.98 The VraX data suggest that S. aureus 
grown under LSMMG may not respond to environmental 
stresses as well as under normal gravity conditions, and the 
accumulative data on the impact of microgravity indicate 
that staphylococci display a biofilm/colonization phenotype 
with reduced virulence characteristics. Strong evidence in 
favor of a LSMMG-induced biofilm/colonization phenotype 
has also been obtained by Castro et al:103 they found that a 
methicillin-resistant S. aureus (MRSA) displayed slower 
growth and repressed virulence characteristics when grown 
under low-shear conditions, including decreased carotenoid 
production, increased susceptibility to oxidative stress, and 
reduced survival in whole blood. Transcriptional profiling 
and expression analysis suggested alterations in metabolic 
pathways and downregulation of the RNA chaperone Hfq, 
which parallels low-fluid-shear responses of Gram-negative 
organisms.94,104
Further evidence that Gram-positive, Gram-negative 
bacteria, and yeasts are less, not more, virulent than 1× g 
controls when grown under microgravity conditions has 
emerged from careful studies of the capacity of Listeria 
monocytogenes, MRSA, Enterococcus faecalis, and Candida 
albicans to kill Caenorhabditis elegans nematodes at the 
larval and adult stages on the ISS and under clinorotation.105 
Spaceflight reduced the virulence of the four microorgan-
isms for both larval and adult C. elegans, and clinorotation 
reproduced the effects of spaceflight in some, but not all, 
virulence assays: C. albicans and E. faecalis were less 
virulent for larval worms but not adult worms, whereas the 
virulence of MRSA and L. monocytogenes were unaffected by 
clinorotation with both adult and larval worms. The authors 
concluded that these four common clinical microorganisms 
are all less virulent in space. Thus, both true and simulated 
space flight environments alter the interactions between host 
and virulent bacteria, and recent evidence suggests that the 
same may be true for animal–bacterial symbiosis,106 with 
implications for human space flight. These authors investi-
gated the impact of simulated microgravity on the timeline 
of bacteria-induced development in the host light organ, the 
site of the symbiosis between the squid Euprymna scolopes, 
and the luminescent bacterium Vibrio fischeri. The host and 
symbiosis-competent bacteria were incubated together in 
the HARV and examined during the early stages of bacteria-
induced morphogenesis. The host innate immune response 
was suppressed under simulated microgravity, and there was 
an acceleration of bacteria-induced apoptosis and regression 
in host tissues, indicating that LSMMG may alter cellular 
interactions between animal hosts and their natural healthy 
microbiome.
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The virulence of Yersinia pestis, the plague bacillus, 
has also been examined under LSMMG with regard to its 
virulence characteristics107 in order to gain insights into 
its pathogenesis. LSMMG-grown cells possessed decreased 
HeLa cell toxicity and proliferated less than normal gravity 
controls in the murine macrophage cell line RAW264.7 as a 
consequence of altered type three secretion system (T3SS) 
function. Thus, a growing body of evidence suggests that 
spaceflight and simulated microgravity conditions reduce, not 
increase, the capacity of pathogenic bacteria (and also yeast) 
to cause infections; this may reduce the risk of infection for 
those undertaking extended space flight, although mutation 
to drug-resistant genotypes during flight may counter this 
presumption. Clearly, much more work needs to be under-
taken in this area and agreement should be reached on the 
precise techniques that will enable meaningful comparisons 
between future studies. True and simulated microgravity 
engender a unique bacterial phenotype that may enable the 
unraveling of mechanisms of microbial pathogenesis and 
drug–bacteria interactions, extending the value of such stud-
ies into the realms of nosocomial and community-acquired 
human infections on Earth.
The space flight environment and 
drug stability: implications for  
anti-infective chemotherapy
The risk of both superficial and systemic infections will 
increase with mission duration,4,43,96 and the high likelihood 
of eye injuries, trauma, and fractures will require antibiotic 
prophylaxis. The onboard pharmacy available to ISS crew 
has been expanded and refined during more than 50 years 
of space faring and its composition reflects the likelihood 
that specific adaptations to microgravity and the health risks 
associated with spaceflight will require frequent therapeutic 
interventions. Although ISS crew members typically spend 
6 months aboard before returning to Earth, comprehensive 
plans are in place for immediate emergency evacuation 
should the need arise.9 Expeditions beyond Earth orbit will 
present enormous health and medical care challenges; lunar 
missions will last weeks or months, and Martian expeditions 
will be of 2–3 years duration with little or no opportunity for 
evacuation of sick crew members.4
The use of pharmaceutical preparations has increased 
with mission length. During the early stages of US Space 
Shuttle missions, crews required .500 individual doses of 
31 different medications; these were administered predomi-
nantly by the oral route to 94% of astronauts.108 Although 
the majority of medicines taken during these flights were 
well tolerated and presumed effective, ∼8% were reported 
as nonefficacious.10 The large number of pharmaceutical 
preparations that comprise the current full medical kit 
aboard the ISS has been described in detail in a recent pub-
lication from the staff at the NASA Johnson Space Center.13 
Antibiotics include amikacin, amoxicillin, co-trimoxazole, 
topical mupirocin, ciprofloxacin as ophthalmic solution 
and tablets, cefadroxil, metronidazole, neosporin cream, 
polymyxin/bacitracin ointment, trimethoprim/polymyxin 
ophthalmic solution, silver sulfadiazine, tobramycin 
ophthalmic solution, vancomycin tablets, sulfacetamide/
prednisolone ophthalmic ointment, and azithromycin. The 
inclusion of antiviral, antifungal, and antiparasitic agents 
ensures that a wide spectrum of infections can be prevented, 
treated, and controlled by medications delivered by a variety 
of routes of administration. The Russian first-aid equipment 
subsystem provides a similar range of antimicrobial formu-
lations.13 All are conventional products from commercial 
sources manufactured to standards required for treatment 
of infections on Earth; they have not been optimized for 
use in LEO or deep space. Further, it is almost certain 
that changes in human physiology and the composition 
of the microbiota will affect the absorption, distribution, 
metabolism, and elimination of drugs taken on board. These 
important issues have only recently begun to receive the 
attention they deserve.
Both the physical stability of the formulation and the 
chemical stability of active ingredients are important in 
ensuring the safe and efficacious use of pharmaceuti-
cal products.14 Evidence is emerging that the conditions 
encountered during even relatively short spaceflight 
adversely affect pharmaceutical stability, and as a conse-
quence, it is essential to identify drugs that have a reduced 
shelf life in LEO and deep space and to provide a means 
for selection and development of medications that will not 
compromise the success of future missions. In this context, 
the physical and chemical stabilities and dissolution rates 
of 35 formulations flown on the ISS have been examined 
and compared to ground controls using US Pharmacopeia 
(USP) standard test criteria.109 After stowage for 28 months 
in space, six medications from the space station and two 
matching ground controls exhibited changes in physical 
variables; nine medications from the ISS and 17 from the 
ground met the USP acceptance criteria for content of the 
active ingredient. A higher percentage of medications from 
each flight kit showed reductions in active ingredient content 
compared to the ground control and the number of medi-
cations failing this requirement increased as a function of 
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time in space. Thus, the rate of degradation of a significant 
number of these medications was higher in space than on 
the ground, although most solid dosage forms met stan-
dards for dissolution after storage in space. This important 
publication from Putcha et al proposed that exposure to 
low doses of ionizing radiation aboard the spacecraft and 
the repackaging of solid dosage forms in flight-specific 
dispensers had adversely affected pharmaceutical stability, 
acting as a wake-up call for the development of space-hardy 
medications.110 The specific contributing factors of the space 
flight environment that are responsible for pharmaceutical 
instability are unknown, but candidates include heat, light, 
vibration, and, particularly, various forms of radiation.
Antibiotic formulations appeared to be prone to degrada-
tion in space: clavulanate in amoxicillin/clavulanate formu-
lations, marketed as Augmentin®, and sulfamethoxazole in 
combination tablets did not meet USP tolerance standards 
after flight and dissolution was very low as a consequence 
of chemical instability. An earlier study along similar lines 
from Du et al111 further established the relative instability of 
antibiotic formulations aboard Space Shuttles and the ISS; 
significant reductions in the percentage label claim for the 
active ingredient were found for amoxicillin capsules and 
ciprofloxacin ointment, and these formulations failed to meet 
regulatory standards post flight. The implications are clear: 
commercially available formulations of established antibi-
otics may not be sufficiently robust to withstand extended 
forays into deep space and use may cause treatment failure. 
Production of bioactive agents from natural product sources 
could be undertaken during extended flight112 and may rep-
resent an alternative source of valuable anti-infective com-
pounds. In a similar fashion, the threat of treatment failure 
during extended flight could be ameliorated by therapeutic 
modalities that are currently attracting interest for the treat-
ment of terrestrial infections, such as photodynamic therapy, 
bacteriophage therapy, and attenuation of bacterial virulence 
by selective removal of key bacterial virulence determinants 
such as the protective surface capsule that allows many patho-
gens to avoid the immune defenses of the host.112,113
Conclusion
The risk of serious infection for spaceflight crew members 
will grow as we journey beyond LEO and into deep space. 
Our ability to treat infections on these journeys may be 
compromised by changes to human physiology and to 
bacterial phenotypes induced by the unique properties of 
the space flight environment. The susceptibility of oppor-
tunistic pathogens to conventional antibiotics may change 
under the influence of microgravity and virulence-related 
characteristics of bacteria – fellow-travelers on board the 
spacecraft – may alter. No clear consensus has emerged 
from the limited amount of data currently available 
regarding long-term risk to crew, and more work needs to 
be  undertaken to gain a clearer picture of the threat posed 
by microorganisms in space.
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